Evidence map›Paper›PMID 31044015›Full record

ArticleLung cancer management2019

Targeting claudin-3 suppresses stem cell-like phenotype in nonsquamous non-small-cell lung carcinoma.

Lin Ma, Wu Yin, Heliang Ma, Ihab Elshoura, Lan Wang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung cancer management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Claudins in Cancer: A Current and Future Therapeutic Target.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Lin MaSchool of Materials Science & Engineering, South China University of Technology, Guangzhou 510640, China.
Wu YinState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210046, China.
Heliang MaDepartment of Radiology, Jinan Central Hospital, Jinan, Shandong 250013, China.
Ihab ElshouraState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210046, China.
Lan WangDepartment of Respiratory Medicine, The Affiliated Jiangyin Hospital of Southeast University, Jiangyin 214400, China.
Nanjing University · CNJiangyin People's Hospital · CNJinan Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo determine the role of claudin-3 in cancer stemness in nonsquamous non-small-cell lung carcinoma (NSCLC). MATERIALS &

methodsRESULTS &

conclusionClaudin-3 depletion decreased the formation rates of spheres and tumors and increased cisplatin sensitivity. Claudin-3 was also identified as one downstream target of estrogen receptor-α in regulating cancer stemness. Moreover, targeting

Indexed as

cancer stemnesscisplatinclaudin-3CSCsELDAestrogen receptor-αnonsquamous NSCLCside populationtight junctiontumorigenesis

Identifiers

PMID31044015
PMCPMC6488947
OpenAlexW2917426018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.